Pravin Dugel - 11 Jun 2025 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Reporting relationship: Executive Chairman, President and CEO. Exhibit 24 - Power of Attorney, Director
Issuer ticker: OCUL
Reported as of: 11 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2025, 16:26:49 UTC
Prior SEC filing: 27 May 2025
Next SEC filing: 27 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel

Key filing fact

Pravin Dugel filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 13 Jun 2025.

Key facts

This page summarizes Pravin Dugel's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2025, 16:26.

Change

Previous filing in this sequence was filed on 27 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001700917 Primary reporting owner

Dugel Pravin

Relationship: Executive Chairman, President and CEO. Exhibit 24 - Power of Attorney, Director
Address: C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD
Signature: /s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel
Signature date: 13 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUL transaction Derivative

Performance Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +2,750,000
Change %
Price: $0.000000
Shares after: 2,750,000
Date: 11 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,750,000
Exercise price: $7.44
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The performance stock option grant was approved by the Board of Directors of Ocular Therapeutix, Inc. (the "Corporation") on February 11, 2025 (the "Grant Date"), the commencement of vesting of which was contingent upon shareholder approval of an amendment to the Corporation's 2021 Stock Incentive Plan, as amended. Shareholder approval of such amendment was received on June 11, 2025.

Footnote F2

Pursuant to a performance stock option agreement (the "Option Agreement"), the shares underlying the performance stock option can be earned during the five-year period beginning on the Grant Date in four equal tranches based on the achievement of share price hurdles if the Corporation's consecutive 60-day closing share price average meets or exceeds $15.00, $20.00, $25.00, and $30.00 per share (each, a "Share Price Hurdle"). Shares underlying the performance stock option that are earned shall vest on the later of (i) the achievement of the applicable Share Price Hurdle or (ii) the three-year anniversary of the Grant Date, in each case subject to the reporting person's continued service to the Corporation. The performance stock option is subject to earlier vesting upon certain qualifying termination events pursuant to the Option Agreement.

SEC remarks

Executive Chairman, President and CEO. Exhibit 24 - Power of Attorney